112 related articles for article (PubMed ID: 38133587)
1. Prognostic significance of C-reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Kaneko S; Asahina Y; Murakawa M; Ueyama S; Maeyashiki C; Watanabe H; Kusano-Kitazume A; Sato A; Uchidate K; Asakawa T; Watanabe S; Iizuka Y; Shibata I; Oooka S; Karakama Y; Fujii T; Watabe T; Akahoshi K; Tanabe M; Inada K; Mochida T; Watakabe K; Shimizu T; Tsuchiya J; Miyoshi M; Kitahata-Kawai F; Nitta S; Nakagawa M; Kakinuma S; Okamoto R;
Hepatol Res; 2023 Dec; ():. PubMed ID: 38133587
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Kaibori M; Iijima H; Hiasa Y; Kumada T;
Hepatol Int; 2022 Oct; 16(5):1150-1160. PubMed ID: 35749019
[TBL] [Abstract][Full Text] [Related]
3. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Teng W; Lin CC; Su CW; Lin PT; Hsieh YC; Chen WT; Ho MM; Wang CT; Chai PM; Hsieh JC; Lin CY; Lin SM
Am J Cancer Res; 2022; 12(4):1899-1911. PubMed ID: 35530282
[TBL] [Abstract][Full Text] [Related]
4. Response Prediction Model of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Retrospective Study.
Ueno M; Kosaka H; Iida H; Ida Y; Aoi K; Mori H; Miyamoto A; Nishida Y; Hayami S; Kawai M; Kaibori M
Oncology; 2023; 101(9):565-574. PubMed ID: 37276856
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
[TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Hatanaka T; Tani J; Takaguchi K; Atsukawa M; Itobayashi E; Nishimura T; Tsuji K; Tajiri K; Ishikawa T; Yasuda S; Toyoda H; Fukunishi S; Ogawa C; Kakizaki S; Shimada N; Naganuma A; Kawata K; Kosaka H; Kuroda H; Matono T; Yata Y; Ochi H; Tada F; Nouso K; Morishita A; Itokawa N; Okubo T; Arai T; Tsutsui A; Nagano T; Yokohama K; Nishikawa H; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kumada T;
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2042. PubMed ID: 38577725
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
Toshida K; Itoh S; Yoshiya S; Nagao Y; Tomino T; Izumi T; Iseda N; Toshima T; Ninomiya M; Yoshizumi T
J Gastroenterol Hepatol; 2024 Mar; 39(3):576-586. PubMed ID: 38084637
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma.
Kuzuya T; Kawabe N; Hashimoto S; Funasaka K; Nagasaka M; Nakagawa Y; Miyahara R; Shibata T; Takahara T; Kato Y; Sugioka A; Hirooka Y
Anticancer Res; 2022 Apr; 42(4):1905-1910. PubMed ID: 35347009
[TBL] [Abstract][Full Text] [Related]
9. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
[TBL] [Abstract][Full Text] [Related]
10. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.
Tada T; Kumada T; Hiraoka A; Kariyama K; Tani J; Hirooka M; Takaguchi K; Atsukawa M; Fukunishi S; Itobayashi E; Tsuji K; Tajiri K; Ochi H; Ishikawa T; Yasuda S; Ogawa C; Toyoda H; Hatanaka T; Nishimura T; Kakizaki S; Kawata K; Shimada N; Tada F; Nouso K; Tsutsui A; Ohama H; Morishita A; Nagano T; Itokawa N; Okubo T; Arai T; Kosaka H; Imai M; Naganuma A; Nakamura S; Koizumi Y; Kaibori M; Iijima H; Hiasa Y;
Cancer Med; 2023 Mar; 12(6):6980-6993. PubMed ID: 36484470
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients.
Toshida K; Itoh S; Tomiyama T; Morinaga A; Kosai Y; Tomino T; Kurihara T; Nagao Y; Morita K; Harada N; Yoshizumi T
JGH Open; 2022 Jul; 6(7):477-486. PubMed ID: 35822124
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
Tanaka K; Tsuji K; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Ishikawa T; Tajiri K; Ochi H; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Matono T; Kuroda H; Yata Y; Ohama H; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Yokohama K; Nishikawa H; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kumada T;
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686624
[TBL] [Abstract][Full Text] [Related]
13. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Tamaki N; Tada T; Kurosaki M; Yasui Y; Ochi H; Mashiba T; Sakamoto A; Marusawa H; Narita R; Uchida Y; Akahane T; Kondo M; Mori N; Takaki S; Tsuji K; Kobashi H; Kusakabe A; Furuta K; Arai H; Nonogi M; Ogawa C; Sato T; Tamada T; Nakamura S; Hasebe C; Tsuchiya K; Izumi N
Invest New Drugs; 2022 Dec; 40(6):1290-1297. PubMed ID: 36152108
[TBL] [Abstract][Full Text] [Related]
14. Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Tada T; Kumada T; Hiraoka A; Kariyama K; Tani J; Hirooka M; Takaguchi K; Atsukawa M; Fukunishi S; Itobayashi E; Tsuji K; Tajiri K; Ochi H; Ishikawa T; Yasuda S; Ogawa C; Toyoda H; Hatanaka T; Nishimura T; Kakizaki S; Kawata K; Shimada N; Tada F; Nouso K; Tsutsui A; Ohama H; Morishita A; Nagano T; Itokawa N; Okubo T; Arai T; Kosaka H; Imai M; Naganuma A; Nakamura S; Koizumi Y; Matono T; Kaibori M; Iijima H; Hiasa Y; ;
Oncology; 2023; 101(4):270-282. PubMed ID: 36455517
[TBL] [Abstract][Full Text] [Related]
15. Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
Kobayashi S; Fukushima T; Ueno M; Chuma M; Numata K; Tsuruya K; Arase Y; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Uojima H; Hidaka H; Kusano C; Morimoto M; Maeda S
Liver Int; 2024 Jun; 44(6):1343-1350. PubMed ID: 38436529
[TBL] [Abstract][Full Text] [Related]
16. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kumada T;
Hepatol Int; 2023 Feb; 17(1):86-96. PubMed ID: 36076009
[TBL] [Abstract][Full Text] [Related]
18. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
[TBL] [Abstract][Full Text] [Related]
19. Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?
Guan R; Mei J; Lin W; Deng M; Li S; Guo R
Hepatol Int; 2023 Oct; 17(5):1279-1288. PubMed ID: 37129721
[TBL] [Abstract][Full Text] [Related]
20. Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kaibori M; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kosaka H; Hiasa Y; Kudo M
Liver Cancer; 2023 Aug; 12(3):209-217. PubMed ID: 37601983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
